Search Results - "de Vos, Filip Y. F"

Cancer patients' trust as a motivator to seek a second opinion and its effects on trust by Hillen, Marij A., Smets, Ellen M. A., M. Stouthard, Jacqueline, de Vos, Filip Y. F., Lehmann, Vicky

“…Cancer patients may seek a second opinion (SO) driven by reduced trust in their own providers. Their trust may be diminished or reinforced through the SO. This…”
Get full text

Prevalence of symptoms in glioma patients throughout the disease trajectory: a systematic review by IJzerman-Korevaar, Margriet, Snijders, Tom J., de Graeff, Alexander, Teunissen, Saskia C. C. M., de Vos, Filip Y. F.

“…Background Glioma patients suffer from a wide range of symptoms which influence quality of life negatively. The aim of this review is to give an overview of…”
Get full text

Characteristics of patients with advanced cancer preferring not to know prognosis: a multicenter survey study by van der Velden, Naomi C. A, van Laarhoven, Hanneke W. M, Burgers, Sjaak A, Hendriks, Lizza E. L, de Vos, Filip Y. F. L, Dingemans, Anne-Marie C, Jansen, Joost, van Haarst, Jan-Maarten W, Dits, Joyce, Smets, Ellen MA, Henselmans, Inge

“…Background For some patients with advanced cancer not knowing prognosis is essential. Yet, in an era of informed decision-making, the potential protective…”
Get full text

Study protocol of the GLOW study: maximising treatment options for recurrent glioblastoma patients by whole genome sequencing-based diagnostics—a prospective multicenter cohort study by van Opijnen, Mark P, Broekman, Marike L. D, de Vos, Filip Y. F, Cuppen, Edwin, van der Hoeven, Jacobus J. M, van Linde, Myra E, Compter, Annette, Beerepoot, Laurens V, van den Bent, Martin J, Vos, Maaike J, Fiebrich, Helle-Brit, Koekkoek, Johan A. F, Hoeben, Ann, Kho, Kuan H, Driessen, Chantal M. L, Jeltema, Hanne-Rinck, Robe, Pierre A. J. T, Maas, Sybren L. N

“…Glioblastoma (GBM), the most common glial primary brain tumour, is without exception lethal. Every year approximately 600 patients are diagnosed with this…”
Get full text

Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial by Subbiah, Vivek, Kreitman, Robert J., Wainberg, Zev A., Gazzah, Anas, Lassen, Ulrik, Stein, Alexander, Wen, Patrick Y., Dietrich, Sascha, de Jonge, Maja J. A., Blay, Jean-Yves, Italiano, Antoine, Yonemori, Kan, Cho, Daniel C., de Vos, Filip Y. F. L., Moreau, Philippe, Fernandez, Elena Elez, Schellens, Jan H. M., Zielinski, Christoph C., Redhu, Suman, Boran, Aislyn, Passos, Vanessa Q., Ilankumaran, Palanichamy, Bang, Yung-Jue

“…BRAFV600E alterations are prevalent across multiple tumors. Here we present final efficacy and safety results of a phase 2 basket trial of dabrafenib (BRAF…”
Get full text

Evaluation of the Khorana, PROTECHT, and 5‐SNP scores for prediction of venous thromboembolism in patients with cancer by Guman, Noori A. M., van Geffen, Roos J., Mulder, Frits I., van Haaps, Thijs F., Hovsepjan, Vahram, Labots, Mariette, Cirkel, Geert A., Y. F. L. de Vos, Filip, ten Tije, Albert J., Beerepoot, Laurens V., Tjan‐Heijnen, Vivianne C. G., van Laarhoven, Hanneke W. M., Hamberg, Paul, Vulink, Annelie J. E., Los, Maartje, Zwinderman, Aeilko H., Ferwerda, Bart, Lolkema, Martijn P. J. K., Steeghs, Neeltje, Büller, Harry R., Kamphuisen, Pieter W., van Es, Nick

“…Background The Khorana score is a validated tool to identify cancer patients at higher risk of venous thromboembolism (VTE). Objective We compared its…”
Get full text

Bevacizumab and temozolomide in patients with first recurrence of WHO grade II and III glioma, without 1p/19q co-deletion (TAVAREC): a randomised controlled phase 2 EORTC trial by van den Bent, Martin J, Klein, Martin, Smits, Marion, Reijneveld, Jaap C, French, Pim J, Clement, Paul, de Vos, Filip Y F, Wick, Antje, Mulholland, Paul J, Taphoorn, Martin J B, Lewis, Joanne, Weller, Michael, Chinot, Olivier L, Kros, Johan M, de Heer, Iris, Verschuere, Tina, Coens, Corneel, Golfinopoulos, Vassilis, Gorlia, Thierry, Idbaih, Ahmed

“…Bevacizumab is frequently used in the treatment of recurrent WHO grade II and III glioma, but without supporting evidence from randomised trials. Therefore, we…”
Get full text

Cognitive impairments are independently associated with shorter survival in diffuse glioma patients by van Kessel, Emma, Huenges Wajer, Irene M. C., Ruis, Carla, Seute, Tatjana, Fonville, Susanne, De Vos, Filip Y. F. L., Verhoeff, Joost J. C., Robe, Pierre A., van Zandvoort, Martine J. E., Snijders, Tom J.

“…Background Diffuse gliomas (WHO grade II–IV) are progressive primary brain tumors with great variability in prognosis. Cognitive deficits are of important…”
Get full text

Whole genome sequencing in (recurrent) glioblastoma: challenges related to informed consent procedures and data sharing by Hasner, Mira C., van Opijnen, Mark P., de Vos, Filip Y. F., Cuppen, Edwin, Broekman, Marike L. D.

“…Increased use of whole genome sequencing (WGS) in neuro-oncology for diagnostics and research purposes necessitates a renewed conversation about informed…”
Get full text

Perfusion imaging with arterial spin labeling (ASL)–MRI predicts malignant progression in low‑grade (WHO grade II) gliomas by Flies, Christina M., Snijders, Tom J., Van Seeters, Tom, Smits, Marion, De Vos, Filip Y. F., Hendrikse, Jeroen, Dankbaar, Jan Willem

“…Purpose Predicting malignant progression of grade II gliomas would allow for earlier initiation of treatment. The hypothesis for this single-centre,…”
Get full text

The role of molecular biomarkers in recurrent glioblastoma trials: an assessment of the current trial landscape of genome-driven oncology by van Opijnen, Mark P., de Vos, Filip Y. F., Cuppen, Edwin, Geurts, Marjolein, Maas, Sybren L. N., Broekman, Marike L. D.

“…For glioblastoma patients, the efficacy-targeted therapy is limited to date. Most of the molecular therapies previously studied are lacking efficacy in this…”
Get full text

Phase 1 study of the pan-HER inhibitor dacomitinib plus the MEK1/2 inhibitor PD-0325901 in patients with KRAS-mutation-positive colorectal, non-small-cell lung and pancreatic cancer by van Geel, Robin M. J. M., van Brummelen, Emilie M. J., Eskens, Ferry A. L. M., Huijberts, Sanne C. F. A., de Vos, Filip Y. F. L., Lolkema, Martijn P. J. K., Devriese, Lot A., Opdam, Frans L., Marchetti, Serena, Steeghs, Neeltje, Monkhorst, Kim, Thijssen, Bas, Rosing, Hilde, Huitema, Alwin D. R., Beijnen, Jos H., Bernards, René, Schellens, Jan H. M.

“…Background Mutations in KRAS result in a constitutively activated MAPK pathway. In KRAS -mutant tumours existing treatment options, e.g. MEK inhibition, have…”
Get full text

Randomized, Open-Label, Crossover Studies Evaluating the Effect of Food and Liquid Formulation on the Pharmacokinetics of the Novel Focal Adhesion Kinase (FAK) Inhibitor BI 853520 by Verheijen, Remy B., van der Biessen, Diane A. J., Hotte, Sebastien J., Siu, Lillian L., Spreafico, Anna, de Jonge, Maja J. A., Pronk, Linda C., De Vos, Filip Y. F. L., Schnell, David, Hirte, Hal W., Steeghs, Neeltje, Lolkema, Martijn P.

“…Background BI 853520 is a potent inhibitor of focal adhesion kinase and is currently under clinical development for the treatment of non-hematological…”
Get full text

Next generation sequencing of high-grade adult-type diffuse glioma in the Netherlands: interlaboratory variation in the primary diagnostic and recurrent setting by van Opijnen, Mark P., Broekman, Marike L. D., Cuppen, Edwin, Dubbink, Hendrikus J., ter Elst, Arja, van Eijk, Ronald, Mühlebner, Angelika, Jansen, Casper, van der Geize, Robert, Speel, Ernst-Jan M., Groenen, Patricia J. T. A., de Vos, Filip Y. F., Wesseling, Pieter, de Leng, Wendy W. J., Maas, Sybren L. N.

“…Purpose Next generation sequencing (NGS) is an important tool used in clinical practice to obtain the required molecular information for accurate diagnostics…”
Get full text

Venous thromboembolism and intracranial hemorrhage after craniotomy for primary malignant brain tumors: a National Surgical Quality Improvement Program analysis by Senders, Joeky T., Goldhaber, Nicole H., Cote, David J., Muskens, Ivo S., Dawood, Hassan Y., De Vos, Filip Y. F. L., Gormley, William B., Smith, Timothy R., Broekman, Marike L. D.

“…Venous thromboembolism (VTE), including deep venous thrombosis (DVT) and pulmonary embolism (PE), frequently complicates the postoperative course of primary…”
Get full text

Limited clinical activity of palbociclib and ribociclib monotherapy in advanced cancers with cyclin D‐CDK4/6 pathway alterations in the Dutch DRUP and Australian MoST trials by Zeverijn, Laurien J., Looze, Eleonora J., Thavaneswaran, Subotheni, Berge Henegouwen, J. Maxime, Simes, Robert J., Hoes, Louisa R., Sjoquist, Katrin M., Wijngaart, Hanneke, Sebastian, Lucille, Geurts, Birgit S., Lee, Chee K., Wit, Gijsbrecht F., Espinoza, David, Roepman, Paul, Lin, Frank P., Jansen, Anne M. L., Leng, Wendy W. J., Noort, Vincent, Leek, Lindsay V. M., Vos, Filip Y. F. L., Herpen, Carla M. L., Gelderblom, Hans, Verheul, Henk M. W., Thomas, David M., Voest, Emile E.

“…The Dutch Drug Rediscovery Protocol (DRUP) and the Australian Cancer Molecular Screening and Therapeutic (MoST) Program are similar nonrandomized, multidrug,…”
Get full text

A dose escalating phase I study of GLPG0187, a broad spectrum integrin receptor antagonist, in adult patients with progressive high-grade glioma and other advanced solid malignancies by Cirkel, Geert A., Kerklaan, Bojana Milojkovic, Vanhoutte, Frédéric, der Aa, Annegret Van, Lorenzon, Giocondo, Namour, Florence, Pujuguet, Philippe, Darquenne, Sophie, de Vos, Filip Y. F., Snijders, Tom J., Voest, Emile E., Schellens, Jan H. M., Lolkema, Martijn P.

“…Summary Background Integrin signaling is an attractive target for anti-cancer treatment. GLPG0187 is a broad spectrum integrin receptor antagonist (IRA)…”
Get full text

Focused Ultrasound-Enhanced Liquid Biopsy: A Promising Diagnostic Tool for Brain Tumor Patients by Bakker, Akke, Ixkes, Anna E, Venugopal, Hema, Ries, Mario G, Lak, Nathalie S M, de Vos, Filip Y F L, van Vuurden, Dannis G, Snijders, Tom J

“…The performance of minimally invasive molecular diagnostic tools in brain tumors, such as liquid biopsy, has so far been limited by the blood-brain barrier…”
Get full text

Comparison of 2-Hydroxyglutarate Detection With sLASER and MEGA-sLASER at 7T by Shams, Zahra, van der Kemp, Wybe J. M., Emir, Uzay, Dankbaar, Jan Willem, Snijders, Tom J., de Vos, Filip Y. F., Klomp, Dennis W. J., Wijnen, Jannie P., Wiegers, Evita C.

“…The onco-metabolite 2-hydroxyglutarate (2HG), a biomarker of IDH-mutant gliomas, can be detected with 1 H MR spectroscopy ( 1 H-MRS). Recent studies showed…”
Get full text

Phase I Study of BI 853520, an Inhibitor of Focal Adhesion Kinase, in Patients with Advanced or Metastatic Nonhematologic Malignancies by de Jonge, Maja J. A., Steeghs, Neeltje, Lolkema, Martijn P., Hotte, Sebastien J., Hirte, Hal W., van der Biessen, Diane A. J., Abdul Razak, Albiruni R., De Vos, Filip Y. F. L., Verheijen, Remy B., Schnell, David, Pronk, Linda C., Jansen, Monique, Siu, Lillian L.

“…Background Overexpression/activation of focal adhesion kinase (FAK) in human malignancies has led to its evaluation as a therapeutic target. We report the…”
Get full text